Teratological study of the antioxidant stobadine in rats.
The potential teratogenicity of the antioxidant stobadine (STO) was studied in Wistar rats. Daily oral doses of 5, 15 and 50 mg/kg STO were given from the 6th day of gestation up to weaning of pups--day 21 post partum. No significant differences between the STO treated groups and the control group were found in litter size, pre- and postimplantation losses and foetal body weight. External, skeletal and internal examinations of the foetuses revealed no evidence of teratogenesis. The offspring from the STO treated dams exhibited a high survival rate in their postnatal development. It can be concluded that STO had no adverse effects on the pre- and postnatal development of the offspring in rats.
Ujházy
E
E
Institute of Experimental Pharmacology, Slovak Academy of Sciences, Bratislava. exfadubm@savba.savba.sk
Dubovický
M
M
Balonová
T
T
Jansák
J
J
D000014:Abnormalities, Drug-Induced; D000818:Animals; D000975:Antioxidants / Q000633:toxicity*; D001835:Body Weight / Q000187:drug effects; D002243:Carbolines / Q000633:toxicity*; D005260:Female; D005313:Fetal Death; D005333:Fetus / Q000187:drug effects; D008098:Litter Size / Q000187:drug effects; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D051381:Rats; D017208:Rats, Wistar; D013723:Teratogens / Q000633:toxicity*
D000975:Antioxidants; D002243:Carbolines; D013723:Teratogens; C100106:dicarbine